Patient First: Aegerion’s Holistic Access & Support Programs
Comprehensive Care for Every Step of the Journey
At Aegerion Pharmaceuticals UK, our commitment to patients with rare diseases doesn’t end with providing innovative therapies—it begins there.
We understand that for many living with rare or ultra-rare conditions, the treatment journey is filled with uncertainty, complexity, and emotional strain. That’s why our Patient Access & Support Programs are built around a simple principle: put the patient first, always.
Our holistic model delivers more than medicine—it delivers personalized, coordinated support designed to remove barriers and improve outcomes.
Why Patient Support Matters in Rare Disease
Patients with rare diseases often face challenges that go beyond clinical care:
Delayed or incorrect diagnosis
Limited availability of specialists
Geographically dispersed treatment centers
Burdensome financial, emotional, and logistical pressures
These obstacles can prevent patients from starting—or continuing—necessary therapy. Aegerion’s programs are designed to address these barriers head-on, ensuring patients and caregivers never feel alone.
Our Patient Access & Support Services
1. Personalized Access Coordination
Our dedicated access teams work closely with patients, healthcare providers, pharmacies, and payers to:
Facilitate prescription fulfilment and authorisation
Navigate NHS and private reimbursement processes
Manage logistics for home or hospital delivery
Offer support for early access and named patient programs, where appropriate
We act as a bridge between clinical prescription and treatment delivery—ensuring no step is left unsupported.
2. Financial Navigation and Affordability Support
We know that affordability concerns can be a major barrier to accessing orphan therapies. Depending on eligibility, we may provide:
Co-pay assistance or financial relief programs
Guidance on NHS-funded access schemes
Support for appeals, prior authorisation, and coverage reviews
Our goal is to ensure cost is never the reason a patient misses out on potentially life-changing treatment.
3. Clinical and Educational Support
Our programs are designed to empower both patients and providers with clear, accurate information. We provide:
Nurse-led education on therapy administration, monitoring, and adherence
Printed and digital materials tailored to patient literacy and language needs
HCP education toolkits for clinics managing rare disease patients
Direct access to Medical Information teams for treatment-related inquiries
We make it easier for patients to understand their condition and for clinicians to provide optimal care.
4. Emotional and Lifestyle Support
Rare diseases often have profound psychological and social impacts. Aegerion supports the whole patient by:
Connecting families with trusted advocacy groups
Offering access to peer support communities
Providing referrals to counselling services or mental health resources when needed
Addressing travel and treatment coordination challenges
Built for the Long Term
Our support doesn’t end after treatment initiation. We stay connected with patients and healthcare teams throughout the therapy lifecycle, offering:
Adherence monitoring and reminders
Ongoing access to educational updates
Feedback loops for continuous improvement
We continuously evolve our programs based on patient insights, regulatory guidance, and changes in healthcare delivery.
Partnering with the Rare Disease Community
Aegerion Pharmaceuticals UK collaborates with:
Patient advocacy groups to co-develop materials and outreach campaigns
Clinical centers of excellence to streamline care pathways
Payers and policy makers to ensure sustainable, long-term support infrastructure
By listening to patient voices and acting on community needs, we’re creating a more inclusive and responsive rare disease ecosystem.
